These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22164947)

  • 21. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
    Messori A; Fadda V; Trippoli S
    J Chemother; 2011 Apr; 23(2):67-70. PubMed ID: 21571620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2003.
    Johnson P
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-25. PubMed ID: 14969256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HTA in Germany: very special and specific.
    Greiner W; von der Schulenburg JM
    Eur J Health Econ; 2010 Feb; 11(1):1-3. PubMed ID: 20087626
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Barer M; Reid RJ
    Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better defining target populations for drugs with a view to reimbursement.
    Massol J; Boissel JP
    Therapie; 2014; 69(3):235-7. PubMed ID: 24927505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Physician versus 'off-label" ordinance].
    Kordus K; Spiewak R
    Przegl Lek; 2015; 72(1):38-41. PubMed ID: 26076577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-label psychotropic prescribing for young persons in medium security.
    Haw C; Stubbs J
    J Psychopharmacol; 2010 Oct; 24(10):1491-8. PubMed ID: 19423609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment off-label prescribing in Dermatology].
    Picard D; Carvalho P; Bonnavia C; Louin L; Josset V; Lauret P; Joly P;
    Ann Dermatol Venereol; 2003 May; 130(5):507-10. PubMed ID: 12843825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do free-of-charge public health services impede cost recovery policies in Khartoum state, Sudan?
    Habbani K; Groot W; Jelovac I
    East Mediterr Health J; 2007; 13(4):939-52. PubMed ID: 17955777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel.
    Gavrilov V; Lifshitz M; Levy J; Gorodischer R
    Isr Med Assoc J; 2000 Aug; 2(8):595-7. PubMed ID: 10979352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Charges billed to third parties for prescription drugs furnished by VA to a veteran for a nonservice-connected disability. Final rule.
    Department of Veterans Affairs
    Fed Regist; 2010 Oct; 75(193):61621-3. PubMed ID: 20931727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
    Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
    JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off-label prescriptions in Italian hospices: a national survey.
    Toscani F; Di Giulio P; Campi R; Pellerin I; De Luca A; Casale G;
    J Pain Symptom Manage; 2009 Sep; 38(3):365-71. PubMed ID: 19564095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
    Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
    ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.